5-(1-Methylethyl)-1H-indole-3-carbonitrile | 194490-21-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5-(1-Methylethyl)-1H-indole-3-carbonitrile
• 英文别名: 5-propan-2-yl-1H-indole-3-carbonitrile
• CAS: 194490-21-6
• 化学式: C₁₂H₁₂N₂
• 分子量: 184.24
• InChiKey: VOOIFVXGVAFWKS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  39.6
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• Modulators of THR-β and methods of use thereof
  申请人：ALIGOS THERAPEUTICS, INC.

  公开号：US11091467B2

  公开（公告）日：2021-08-17

  Disclosed herein are compounds of Formula I: TL-La-CE-HD  (I) or a pharmaceutically acceptable salt, prodrug, amide or ester thereof, where i) TL is a moiety of Formula IIa, IIb, IIIa, IIIb, IIIc, or IIId; ii) CE is a moiety of Formula IV; iii) HD is a moiety of Formula V or VI; where the substituents are as defined herein. Disclosed are also pharmaceutical compositions comprising the above compounds, and methods of treating disease by administering or contact a patient with one or more of the above compounds.

  本文公开了式 I 的化合物： TL-La-CE-HD (I) 或其药学上可接受的盐、原药、酰胺或酯，其中 i) TL 是式 IIa、IIb、IIIa、IIIb、IIIc 或 IIId 的分子；ii) CE 是式 IV 的分子；iii) HD 是式 V 或 VI 的分子；其中取代基如本文所定义。还公开了包含上述化合物的药物组合物，以及通过给患者施用或接触一种或多种上述化合物来治疗疾病的方法。
• MODULATORS OF THR-BETA AND METHODS OF USE THEREOF
  申请人：ALIGOS THERAPEUTICS, INC.

  公开号：US20200354345A1

  公开（公告）日：2020-11-12

  Disclosed herein are compounds of Formula I: TL-L a -CE-HD  (I) or a pharmaceutically acceptable salt, prodrug, amide or ester thereof, where i) TL is a moiety of Formula IIa, IIb, IIIa, IIIb, IIIc, or IIId; ii) CE is a moiety of Formula IV; iii) HD is a moiety of Formula V or VI; where the substituents are as defined herein. Disclosed are also pharmaceutical compositions comprising the above compounds, and methods of treating disease by administering or contact a patient with one or more of the above compounds.
• New Organic Compounds
  申请人：Servier Pharmaceuticals LLC

  公开号：US20220169654A1

  公开（公告）日：2022-06-02

  The present application provides MAT2A inhibitor compounds that are useful as therapeutic agents. In some embodiments, the compounds are of Formula I, or pharmaceutically acceptable salts thereof: wherein R 1 , R 2 , and X 1 -X 3 are defined herein.